SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023)

SAB Biotherapeutics (SABS) posted Convertible Debt of $541644.0 for Q2 2023, little changed on a QoQ basis from $541644.0 in Q1 2023.

SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023) Analysis & Trends

SAB Biotherapeutics' Convertible Debt history runs 2 years deep, the most recent figure standing at $541644.0 for Q2 2023.

Quarterly Convertible Debt changed N/A year-over-year to $541644.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $541644.0 (changed N/A YoY) and the FY2022 annual result came in at $541644.0, changed N/A from the prior year.
Convertible Debt was $541644.0 for Q2 2023 at SAB Biotherapeutics, roughly flat from $541644.0 in the prior quarter.
Across five years, Convertible Debt topped out at $541644.0 in Q4 2022 and bottomed at $541644.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	SAB Biotherapeutics	170.64 Mn	170.64 Mn	-

Download Data